Quantitative followup study of the driver mutation fraction in cell-free DNA from non small cell lung cancer patient during TKI therapy - Quantitative followup study of the driver gene mutation in cell-free DNA

Methods: 33 cfDNA samples from patients who received EGFR-TKI therapy for tumor with sensitive mutations were subjected to a pdPCR-based examination of the proportion of sensitive mutant cfDNAs with the T790M mutation. Results: sensitive mutations were detected in all 8 samples obtained after acquisition of resistance to TKIs and T790M mutation were positive in 5 of the samples. Conclusions: pdPCR-based examination of cfDNAs represents a robust non-invasive assessment of tumor progression status.